글로벌 연구동향
핵의학
- 2018년 07월호
[Endocr Relat Cancer.] Diagnostic performance of PET in thyroid cancer with elevated anti-Tg Ab.부산대 / 김성장*
- 출처
- Endocr Relat Cancer.
- 등재일
- 2018 Jun
- 저널이슈번호
- 25(6):643-652. doi: 10.1530/ERC-17-0341. Epub 2018 Mar 20.
- 내용
Abstract
We aimed to explore the role of the diagnostic accuracy of F-18 fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) for the detection of recurrent and/or metastatic diseases in differentiated thyroid cancer (DTC) patients with progressively and/or persistently elevated TgAb levels and negative radioactive iodine whole-body scan (RI-WBS) through a systematic review and meta-analysis. The MEDLINE, EMBASE and Cochrane Library database, from the earliest available date of indexing through June 30, 2017, were searched for studies evaluating the diagnostic performance of F-18 FDG PET/CT for the detection of recurrent and/or metastatic diseases in DTC patients with progressively and/or persistently elevated TgAb levels and negative RI-WBS. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-). Across 9 studies (515 patients), the pooled sensitivity for F-18 FDG PET/CT was 0.84 (95% CI; 0.77-0.89) a pooled specificity of 0.78 (95% CI; 0.67-0.86). Likelihood ratio (LR) syntheses gave an overall positive likelihood ratio (LR+) of 3.8 (95% CI; 2.5-5.7) and negative likelihood ratio (LR-) of 0.21 (95% CI; 0.14-0.30). The pooled diagnostic odds ratio (DOR) was 18 (95% CI; 10-34). The area (AUC) under the hierarchical summary receiver-operating characteristic (HCROC) curve was 0.88 (95% CI: 0.85-0.90). F-18 FDG PET or PET/CT demonstrated moderate sensitivity and specificity for the detection of recurrent and/or metastatic diseases in DTC patients with progressively and/or persistently elevated TgAb levels and negative RI-WBS.
Author informationKim SJ1,2,3, Lee SW4,5, Pak K6, Shim SR7.
1
Department of Nuclear MedicinePusan National University Yangsan Hospital, Yangsan, Korea growthkim@pusan.ac.kr.
2
BioMedical Research Institute for Convergence of Biomedical Science and TechnologyPusan National University Yangsan Hospital, Yangsan, Korea.
3
Department of Nuclear MedicineCollege of Medicine, Pusan National University, Yangsan, Korea.
4
Department of Nuclear MedicineSchool of Medicine, Kyungpook National University, Daegu, Korea.
5
Department of Nuclear MedicineKyungpook National University Hospital, Daegu, Korea.
6
Department of Nuclear MedicinePusan National University Hospital, Busan, Korea.
7
Institute for Clinical Molecular Biology ResearchSoonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
- 키워드
- PET/CT; anti-thyroglobulin antibody; positron emission tomography; thyroid neoplasm
- 연구소개
- 갑상선암에서 FDG PET의 재발/전이 발견 진단성적에 대한 메타분석 연구로서 특히 anti-Tg Ab가 증가하고 radioactive iodine whole-body scan에서 negative인 경우에 대하여 분석한 연구입니다. 9개의 연구를 통해 확인된 결과로는, PET의 sensitivity는 0.84, specificity는 0.78입니다.
- 덧글달기
- 이전글 [Eur J Nucl Med Mol Imaging.] The roles of 11C-acetate PET/CT in predicting tumor differentiation and survival in patients with cerebral glioma.
- 다음글 [AJR Am J Roentgenol.] Relation of EGFR Mutation Status to Metabolic Activity in Localized Lung Adenocarcinoma and Its Influence on the Use of FDG PET/CT Parameters in Prognosis.
편집위원
FDG PET이 갑상선암의 재발 진단에 유용함을 보여준 좋은 연구로 국내에서 갑상선암에서 FDG PET의 보험제약을 해소하는데 도움이 될 수 있는 갑진 연구결과임. 내분비, 종양, 핵의학 관련 임상의사에게 중요한 정보를 제공할 수 있음.
덧글달기닫기2018-07-12 14:59:55
등록
편집위원2
systematic review를 통해 Tg-Ab positive, Iodine scan에서 negative인 갑상선암 환자에서 FDG PET의 유용성을 잘 보여주었습니다. 갑상선암에서 적절한 핵의학 검사의 indication을 위해 근거를 잘 보여준 연구입니다.
덧글달기닫기2018-07-12 15:08:58
등록